Table 1 Baseline patient demographic and disease characteristics
Everlimus (N = 18) | |
|---|---|
Age in years, median (range) | 29(20~ 46) |
< 30 year | 9(50%) |
≥ 30 year | 9(50%) |
Sex | |
Women | 12(66.7%) |
Men | 6(33.3%) |
Gene mutation | |
TSC1 | 0(0%) |
TSC2 | 18(100%) |
Diagnosis of lymphangioleiomyomatosis | 6(33.3%) |
Skin lesion(≥1) | 18(100%) |
Presence of subepedymal giant cell astrocytoma | 1(5.6%) |
Longest diameter of the largest renal angiomyolipoma lesion | |
≥ 8 cm | 14(77.8%) |
≥ 4 cm and < 8 cm | 4(22.2%) |
< 4 cm | 0(0%) |
Sum of volumes of target renal angiomyolipoma lesions, cm3 | |
Mean (SD) | 1974 (2406) |
Median (range) | 1247 (60.77~ 9079) |
Bilateral angiomyolipoma | 16(88.9%) |
Number of target angiomyolipoma lesions | |
1~ 2 | 11(61.1%) |
3~ 4 | 7(38.9%) |
Previous angiomyolipoma therapy | |
Surgery/invasive procedure | 6(33.3%) |
Renal embolisation | 2(11.1%) |
Partial nephrectomy | 2(11.1%) |
Nephrectomy | 2(11.1%) |
Medication | 0(0%) |